2023
DOI: 10.3390/jcm12134362
|View full text |Cite
|
Sign up to set email alerts
|

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

Abstract: Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous studies have tested the therapeutic switch between two biologics with excellent results, further demonstrating the heterogeneity of asthmatic disease and the complexity of the therapeutic choice. It remains unclear if such patients may improve following a switc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…The rehabilitation of NK cells may also positively implicate enhanced protection against infections and/or cancer (61). All these immunological aspects, as well as its PK, can explain the clinical success of this mAb, as highlighted by several clinical key indicators of efficacy, such as the high proportion of patients achieving clinical remission up to 3 years (43,50)the control of these patients even in cases of failure of previous biologic treatment (9,63); the magnitude of its OCS-sparing effect that can often lead to complete oral steroid elimination in severe eosinophilic patients, while maintaining or even improving disease control (14,44). In other words, the complex and unique multiple modes of actions of benralizuamb and its PK features, seem to be the milestone on which the effectiveness of benralizumab is founded.…”
Section: Concluding and Innovative Remarksmentioning
confidence: 99%
See 1 more Smart Citation
“…The rehabilitation of NK cells may also positively implicate enhanced protection against infections and/or cancer (61). All these immunological aspects, as well as its PK, can explain the clinical success of this mAb, as highlighted by several clinical key indicators of efficacy, such as the high proportion of patients achieving clinical remission up to 3 years (43,50)the control of these patients even in cases of failure of previous biologic treatment (9,63); the magnitude of its OCS-sparing effect that can often lead to complete oral steroid elimination in severe eosinophilic patients, while maintaining or even improving disease control (14,44). In other words, the complex and unique multiple modes of actions of benralizuamb and its PK features, seem to be the milestone on which the effectiveness of benralizumab is founded.…”
Section: Concluding and Innovative Remarksmentioning
confidence: 99%
“…Benralizumab is a mAb targeting IL-5Rα on eosinophils, basophils, mast cells and other cells (7). Its effectiveness in SEA is well established, reducing asthma exacerbations and oral corticosteroid (OCS) use and improving lung function, asthma control and quality of life (8,9). Benralizumab induces eosinophil apoptosis through an antibody-dependent cell-mediated cytotoxicity (ADCC) 2 mechanism mediated by natural killer (NK) cells and macrophages, significantly reducing peripheral eosinophils (10,11).…”
Section: Introductionmentioning
confidence: 99%